A texaphyrin–oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells†
Abstract
A
* Corresponding authors
a
Department of Chemistry and Biochemistry, Texas Institute for Diagnostics and Drug Development, The University of Texas, 1 University Station-A5300, Austin, TX 78712-0165, USA
E-mail:
sessler@mail.utexas.edu
Fax: +1 512 471 7550
Tel: +1 512 471 5009
b
Department of Experimental Therapeutics, UT M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 353, Houston, TX 77030, USA
E-mail:
zsiddik@mdanderson.org
Fax: +1 713 792 1204
Tel: +1 713 792 7746
A
J. F. Arambula, J. L. Sessler and Z. H. Siddik, Med. Chem. Commun., 2012, 3, 1275 DOI: 10.1039/C2MD20206A
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content